BridgeBio Pharma Expands European Presence with $300 Million Royalty Monetization Deal for BEYONTTRA
Reuters
Jun 30, 2025
BridgeBio Pharma Expands European Presence with $300 Million Royalty Monetization Deal for BEYONTTRA
BridgeBio Pharma Inc. has bolstered its financial position by securing $300 million through a partial monetization of European royalties for its drug, BEYONTTRA. This strategic move involves selling 60% of royalties on the first $500 million of annual net sales in Europe, capped initially at 1.45x, with funds managed by HCRx and Blue Owl. The transaction supports the launch of Attruby and the development of BridgeBio's late-stage pipeline programs. BEYONTTRA, known as Attruby in the U.S., is approved for treating ATTR-CM and reflects significant commercial potential. This expansion is further reinforced by an exclusive licensing agreement with Bayer Consumer Care AG for European commercialization, with BridgeBio set to receive milestone payments and tiered royalties.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BridgeBio Pharma Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9486502-en) on June 30, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.